ArticleHuman mutation2026
Experimental Validation and Bioinformatics Analysis Elucidate the Role of MTDH-Mediated PTEN Ubiquitination and Degradation in Podocyte Injury in Diabetic Kidney Disease.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) stands as a primary contributor to end-stage renal disease. Podocyte injury is a key factor underlying proteinuria in DN. Metadherin (MTDH) participates in podocyte apoptosis and promotes renal tubular injury in DN. However, its role in podocyte damage and podocyte cytoskeleton remodeling requires further investigation. PTEN plays a crucial role in maintaining podocyte integrity; however, the mechanisms governing PTEN stability in DN remain poorly understood. This study is aimed at investigating the specific functional role of MTDH in PTEN regulation using db/db diabetic mice, human kidney biopsy samples from DN patients, and cultured mouse podocytes exposed to high glucose (HG). MTDH expression was markedly increased in DN kidneys and HG-stimulated podocytes. Elevated MTDH resulted in decreased PTEN protein expression levels without altering PTEN mRNA expression, suggesting a posttranscriptional regulatory mechanism. Further assays demonstrated that MTDH promoted PTEN degradation through the ubiquitin-proteasome pathway. Through bioinformatics analysis of the GSE96804 dataset from the Gene Expression Omnibus (GEO) database, obtaining 13,289 differentially expressed genes and comparing them with the known ubiquitin ligase-encoding genes obtained from the Genecards database, we identified candidate hub genes involved in PTEN ubiquitination-mediated degradation. RNA sequencing identified ubiquitin-conjugating enzyme E2N (UBE2N) as a critical downstream mediator positively regulated by MTDH. Subsequent coimmunoprecipitation experiments confirmed direct interactions between PTEN and UBE2N, enhancing PTEN ubiquitination. Knockdown of UBE2N attenuated MTDH-induced PTEN degradation and podocyte cytoskeletal remodeling. Collectively, our findings reveal a novel regulatory axis wherein MTDH accelerates PTEN ubiquitination and proteasomal degradation via UBE2N, contributing to podocyte injury in DN. Targeting MTDH-driven PTEN ubiquitination degradation presents a promising therapeutic strategy to protect podocytes and mitigate diabetic kidney injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.